Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England.
Vanessa QuickMahdi AbusalamehSajeel AhmedHoda AlkokyMarwan BukhariStuart CarterFiona Louise CoathBrian DavidsonParveen DoddamaniShirish DubeyGeorgina DuckerBridget GriffithsNicola J GullickJonathan HeaneyAmelia HollowayEi Ei Phyu HtutMark HughesHannah IrvineAlison KinderAsim KurshidJoyce Tau Shin LimDalia R LudwigMariam MalikLouise MercerBen MulhearnJagdish R NairRikesh PatelJoanna C RobsonPratyasha SahaSarah L Tansleynull nullSarah Louise MackiePublished in: Rheumatology (Oxford, England) (2023)
Up to half our patients with GCA relapsed after stopping qwTCZ, often requiring a substantial increase in prednisolone dose. One third of relapsers had a major relapse. Extended use of TCZ or repeat treatment for relapse should be considered for these patients.
Keyphrases
- giant cell
- end stage renal disease
- free survival
- newly diagnosed
- ejection fraction
- healthcare
- chronic kidney disease
- mental health
- acute lymphoblastic leukemia
- rheumatoid arthritis
- clinical trial
- peritoneal dialysis
- prognostic factors
- diffuse large b cell lymphoma
- randomized controlled trial
- multiple myeloma
- study protocol
- systemic lupus erythematosus